
Opinion|Videos|May 26, 2025
Long-Term Success: Educating and Supporting Patients on ALK Inhibitors
Panelists discuss how proactive patient education, lipid-lowering interventions, and monitoring tools can help patients stay on ALK inhibitor therapy to realize long-term benefits.
Advertisement
Episodes in this series

ALK Inhibitor Therapy Management
Main Discussion Topics
- Patient education strategies for lorlatinib therapy adherence
- Lipid-lowering interventions to support long-term lorlatinib treatment
- Monitoring tools for patients on ALK inhibitors
- Patient education methodologies specific to ALK inhibitor therapy
Discussion Questions Posed
- Grizzard inquired about proactive patient education and lipid-lowering interventions to help patients maintain lorlatinib therapy for long-term benefits
Castronovo asked about potentially useful tools for educating and monitoring patients on ALK inhibitors
Advertisement
Related to this article

Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.

These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.

Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.

At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.

AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.

The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).

Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
3
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
4
MedHaul Closes Care Gaps With Single Stop for Getting Patients to Appointments
5

